Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available

Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.

Related Keywords

United States ,Leah Mccormick Howard ,National Psoriasis Foundation ,Optum Specialty ,Psoriasis ,Bimzelx ,Bimekizumab ,Plaque Psoriasis ,